Efficacy of ledipasvir/sofosbuvir with or without ribavirin for 12 weeks in genotype 1b HCV patients previously treated with a nonstructural protein 5A inhibitor-containing regimen.

Hiroki IkedaTsunamasa WatanabeHirohito ShimizuTetsuya HiraishiRena KanekoToshiyuki BabaHideaki TakahashiKotaro MatsunagaNobuyuki MatsumotoHiroshi YasudaChiaki OkuseShogo IwabuchiMichihiro SuzukiFumio Itoh

Published in: Hepatology research : the official journal of the Japan Society of Hepatology (2018)

The addition of RBV to 12 weeks of LDV/SOF has little therapeutic benefit when retreating patients in whom a prior NS5A inhibitor-containing regimen had failed.

Keyphrases

end stage renal disease
newly diagnosed
ejection fraction
hepatitis c virus
prognostic factors
peritoneal dialysis
gestational age
binding protein